Phase I Trial to Evaluate the Safety of Intralesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma This investigator-initiated, phase II, multicenter, single-arm trial enrolled patients with ...
Cellular proliferation and tumor suppression pathways as potential targets in clinically aggressive sarcomas.
SHELTON, Conn., June 30, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results